CG Oncology Inc
NASDAQ:CGON
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.84
47.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
CGON Price Targets Summary
CG Oncology Inc
According to Wall Street analysts, the average 1-year price target for CGON is 69.36 USD with a low forecast of 52.52 USD and a high forecast of 90.3 USD.
CGON Last Price Targets
CG Oncology Inc
The latest public price target was made on Sep 17, 2024 by Andres Maldonado from H.C. Wainwright , who expects CGON stock to rise by 92% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Andres Maldonado
H.C. Wainwright
|
75
USD
Upside 92% |
4 days ago
Sep 17, 2024
|
H.C. Wainwright Reiterates Buy Rating on CG Oncology (CGON)
StreetInsider
|
Corinne Johnson
Goldman Sachs
|
52
USD
Upside 33% |
5 days ago
Sep 16, 2024
|
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
StreetInsider
|
|
Corinne Johnson
Goldman Sachs
|
50
USD
Upside 28% |
4 months ago
May 13, 2024
|
CG Oncology upgraded to Buy from Neutral at Goldman Sachs
TheFly
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CGON's stock price target?
Price Target
69.36
USD
According to Wall Street analysts, the average 1-year price target for CGON is 69.36 USD with a low forecast of 52.52 USD and a high forecast of 90.3 USD.
What is CG Oncology Inc's Revenue forecast?
Projected CAGR
660%
For the last 1 year the compound annual growth rate for CG Oncology Inc's revenue is 7%. The projected CAGR for the next 3 years is 660%.
You don't have any saved screeners yet
